Loading…
Pandemic Preparedness, Response, and Recovery Act of 2021
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 5,357 other S bills in the 117th — cohort avg 38d
Pandemic Preparedness, Response, and Recovery Act of 2021 This bill establishes in the legislative branch the Pandemic Preparedness, Response, and Recovery Commission to make recommendations and propose legislation for modification, consolidation, harmonization, or repeal of regulations to reduce compliance costs, encourage growth and innovation, improve competitiveness, and protect public safety. The commission must give priority to regulations (1) the repeal or modification of which may assist recovery or response to the COVID-19 (i.e., coronavirus disease 2019) pandemic and future pandemics, (2) that impose disproportionately high costs on a small entity, (3) that create substantial recurring paperwork burdens or transaction costs, or (4) that could be made more effective while reducing regulatory costs. The bill sets forth reporting requirements for the commission and procedures for congressional consideration of commission reports, recommendations, and proposed legislation.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (3)
2024 · first_quarter · Health Issues
Prescription drug rebates in federal health programs Reform to the Centers for Medicare and Medicaid Innovation (CMMI) Inflation Reduction Act's changes to prescription drug pricing in Medicare H.R. 3353Contact Lens Prescription Verification Modernization Act (117th Congress) S. 1001 / H.R. 1843Telehealth Expansion Act H.R. 9160Healthcare Freedom Act (117th Congress) Pharmacy benefit manager (PBM) reform H.R. 3682Improving Transparency to Lower Drug Costs Act (117th Congress) Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act Enhanced PBM spread pricing transparency in Medicaid Enhanced specialty pharmacy reporting in Medicare Part D Reducing Medicare conflicts of interest in pharmacy and therapeutics (P&T) committees Biden administration proposal to expand Medicare price negotiation in FY 2024 budget S. 1644 / H.R. 3761Promising Pathway Act (117th Congress) Reforms to FDA review and approval Updates to Medicare reimbursement procedures for new drugs S. 1038 / H.R. 1613Drug Pricing Transparency in Medicaid Act H.R. 977Patient Access to Higher Quality Health Care Act of 2023 340B Program transparency and oversight H.R. 2679Pharmacy Benefits Manager Accountability Act Site-neutral payments in Medicare S. 1869 Site-based Invoicing and Transparency Enhancement (SITE) Act H.R.3799CHOICE Arrangement Act S. 2333Pandemic and All-Hazards Preparedness Act HR 4818Treat and Reduce Obesity Act S. 2254 / H.R 5385Medicare PBM Accountability Act HR 1843Telehealth Expansion Act H.R. 2880Protecting Patients Against PBM Abuses Act HR 2748Contact Lens Prescription Verification Modernization Act (117th Congress)
Read twice and referred to the Committee on Homeland Security and Governmental Affairs.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: $30,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2023 · fourth_quarter · Health Issues
Prescription drug rebates in federal health programs Reform to the Centers for Medicare and Medicaid Innovation (CMMI) Inflation Reduction Act's changes to prescription drug pricing in Medicare H.R. 3353Contact Lens Prescription Verification Modernization Act (117th Congress) S. 1001 / H.R. 1843Telehealth Expansion Act H.R. 9160Healthcare Freedom Act (117th Congress) Pharmacy benefit manager (PBM) reform H.R. 3682Improving Transparency to Lower Drug Costs Act (117th Congress) Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act Enhanced PBM spread pricing transparency in Medicaid Enhanced specialty pharmacy reporting in Medicare Part D Reducing Medicare conflicts of interest in pharmacy and therapeutics (P&T) committees Biden administration proposal to expand Medicare price negotiation in FY 2024 budget S. 1644 / H.R. 3761Promising Pathway Act (117th Congress) Reforms to FDA review and approval Updates to Medicare reimbursement procedures for new drugs S. 1038 / H.R. 1613Drug Pricing Transparency in Medicaid Act H.R. 977Patient Access to Higher Quality Health Care Act of 2023 340B Program transparency and oversight H.R. 2679Pharmacy Benefits Manager Accountability Act Site-neutral payments in Medicare S. 1869 Site-based Invoicing and Transparency Enhancement (SITE) Act H.R.3799CHOICE Arrangement Act S. 2333Pandemic and All-Hazards Preparedness Act HR 4818Treat and Reduce Obesity Act S. 2254 / H.R 5385Medicare PBM Accountability Act HR 1843Telehealth Expansion Act H.R. 2880Protecting Patients Against PBM Abuses Act
Client expense: $30,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2023 · third_quarter · Health Issues
Prescription drug rebates in federal health programs Reform to the Centers for Medicare and Medicaid Innovation (CMMI) Inflation Reduction Act's changes to prescription drug pricing in Medicare H.R. 3353Contact Lens Prescription Verification Modernization Act (117th Congress) S. 1001 / H.R. 1843Telehealth Expansion Act H.R. 9160Healthcare Freedom Act (117th Congress) Pharmacy benefit manager (PBM) reform H.R. 3682Improving Transparency to Lower Drug Costs Act (117th Congress) Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act Enhanced PBM spread pricing transparency in Medicaid Enhanced specialty pharmacy reporting in Medicare Part D Reducing Medicare conflicts of interest in pharmacy and therapeutics (P&T) committees Biden administration proposal to expand Medicare price negotiation in FY 2024 budget S. 1644 / H.R. 3761Promising Pathway Act (117th Congress) Reforms to FDA review and approval Updates to Medicare reimbursement procedures for new drugs S. 1038 / H.R. 1613Drug Pricing Transparency in Medicaid Act H.R. 977Patient Access to Higher Quality Health Care Act of 2023 340B Program transparency and oversight H.R. 2679Pharmacy Benefits Manager Accountability Act Site-neutral payments in Medicare S. 1869 Site-based Invoicing and Transparency Enhancement (SITE) Act H.R.3799CHOICE Arrangement Act S. 2333Pandemic and All-Hazards Preparedness Act HR 4818Treat and Reduce Obesity Act
Client expense: $30,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2023 · first_quarter · Health Issues
Potential improvements and modifications to the Affordable Care Act (ACA) Prescription drug rebates in federal health programs Reform to the Centers for Medicare and Medicaid Innovation (CMMI) Proposals to expand Medicare, Medicaid, and ACA premium tax credits in the Inflation Reduction Act Repealing or delaying the Trump administration's rebate rule Inflation Reduction Act's changes to prescription drug pricing in Medicare H.R. 3353Contact Lens Prescription Verification Modernization Act (117th Congress) S. 3700 / H.R. 6833Affordable Insulin Now Act (117th Congress) S. 1001 / H.R. 1843Telehealth Expansion Act Health Savings Account (HSA) expansion H.R. 9160Healthcare Freedom Act (117th Congress) Pharmacy benefit manager (PBM) reform H.R. 3682Improving Transparency to Lower Drug Costs Act (117th Congress) Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act Enhanced PBM spread pricing transparency in Medicaid Enhanced specialty pharmacy reporting in Medicare Part D Reducing Medicare conflicts of interest in pharmacy and therapeutics (P&T) committees Biden administration proposal to expand Medicare price negotiation in FY 2024 budget S. 1644 / H.R. 3761Promising Pathway Act (117th Congress) Reforms to FDA review and approval Updates to Medicare reimbursement procedures for new drugs S. 1038 / H.R. 1613Drug Pricing Transparency in Medicaid Act RIN: 3084-AB37Eyeglass Rule
Client expense: $30,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, SENATE
2023 · first_quarter · Health Issues
* Issues related to surprise billing law and regulation. * Issues related to P.L. 117-328, the Consolidated Appropriations Act 2023, including telehealth and redeterminations. * Issues related to P.L. 117-169, the Inflation Reduction Act of 2022, including enhanced advance premium tax credits (APTCs) and Medicare Part D redesign. * Issues related to S. 113, the Prescription Pricing for the People Act, and S. 127, the Pharmacy Benefit Manager Transparency Act. * Issues related to removing barriers to biosimilar medicine access. * Issues related to insulin pricing. * Issues related to mental health coverage, workforce, and mental health parity. * Issues related to Quality-Adjusted Life Year (QALY) or similar metrics in health coverage legislation. * S. 1001, Issues related to the Telehealth Expansion Act. * Issues related to the proposed rule on Advancing Interoperability and Improving Prior Authorization Processes for Medicare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Childrens Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, Issuers of Qualified Health Plans on the Federally-facilitated Exchanges, Merit-based Incentive Payment System (MIPS) Eligible Clinicians, and Eligible Hospitals and Critical Access Hospitals in the Medicare Promoting Interoperability Program.
Client expense: $5,210,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · second_quarter · Health Issues
Issues regarding eligibility for, implementation of Health Savings Accounts: H.R. 295, Pandemic Healthcare Access Act; H.R. 725/S.153, Personalized Care Act; S.1001, Pandemic Preparedness, Response, and Recovery Act of 2021. Issues regarding telehealth access (no specific legislation). Support for H.R. 3035, Preventing Foreign Attempts to Erode Healthcare Innovation Act and H.R. 471, PAUSE Act (entire legislation). Issues regarding retirement healthcare access, H.R. 1166/S.275, Retirement Freedom Act. Issues regarding vaccine passports (no specific legislation).
Client expense: $10,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
| Republican |
| UT |
| Ron Johnson | Republican | WI |